Product Highlight - HERNEXEOS

First-in-class, Once-daily, oral HER2-targeted TKI for previously treated HER2-mutant metastatic NSCLC¹

• Objective Response Rate (ORR) 71% (95% CI: 60-80; n=53/75; P<0.001)^1,2

• Median duration of response (mDOR) 14.1 months (95% CI: 6.9-NE; n=53)^1,2

• Median progression-free survival (mPFS) 12.4 months in BEAMION^® LUNG-1 (95% CI: 8.2-NE; n=75)^1,2

• Favourable tolerability profile, with Grade 3 diarrhea reported in 1% and treatment discontinuation in 3% of patients^1,2

• Convenient once-daily oral administration^1,2

NE = not evaluable

References:
1. Heymach JV, Ruiter G, Ahn M-J, et al; Beamion LUNG-1 Investigators. Zongertinib in previously treated HER2-mutant non-small-cell lung cancer. N Engl J Med. 2025;392(23):2321-2333.
2. Hong Kong Prescribing Information (HERNEXEOS^®).


PC-HK-101830 (June 2026)